ASCO GI 2021 | Liposomal irinotecan + fluorouracil/leucovorin after progression in mPDAC

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, outlines the results of an analysis evaluating the clinical benefit of liposomal irinotecan plus fluorouracil/leucovorin after conventional irinotecan-containing chemotherapy for patients with metastatic pancreatic adenocarcinoma (mPDAC). In this patient population, the addition of liposomal irinotecan plus fluorouracil/leucovorin showed only modest efficacy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).